D-TECT: Pretreatment D-dimers and Disease Control in Advanced cSCC Treated With Cemiplimab

ClinicalTrials.gov ID

NCT07684066

Lead Sponsor

Universitätsklinikum Hamburg-EppendorfOTHER

Overall Status

Not yet recruiting

Study Type

Observational

Enrollment

116Estimated

Last Update Posted

Jul 22, 2026Actual

Start Date

Aug 1, 2026Estimated

Primary Completion Date

Jul 31, 2028Estimated

Completion Date

Mar 31, 2030Estimated

Official Title

D-TECT: Prospective Multicenter Evaluation of Pretreatment D-dimer Levels as a Predictor of Disease Control in Advanced Cutaneous Squamous Cell Carcinoma Treated With Cemiplimab

Brief Summary

D-TECT is a prospective, multicenter, non-interventional observational study investigating whether pretreatment D-dimer levels predict disease control in patients with locally advanced or metastatic cutaneous squamous cell carcinoma treated with cemiplimab in routine clinical care.

D-dimers are routinely available laboratory markers related to activation of the coagulation system. Previous single-center data suggest that elevated pretreatment D-dimer levels may be associated with poorer disease control under cemiplimab. In D-TECT, a single pretreatment D-dimer value and prospectively collected routine clinical follow-up data will be analyzed to validate this association in a multicenter real-world setting. No study-specific treatment decisions, imaging procedures, or additional blood draws are mandated by the study.

Detailed Description

Cutaneous squamous cell carcinoma (cSCC) is one of the most common skin cancers. While most cases can be treated with curative local therapy, a subgroup of patients develops locally advanced or metastatic disease requiring systemic treatment. Cemiplimab, a PD-1 inhibitor, is an established systemic treatment option for advanced cSCC. However, validated routine biomarkers predicting disease control under cemiplimab are lacking.

D-dimers are fibrin degradation products and sensitive markers of coagulation activation. In a prior single-center retrospective analysis, elevated pretreatment D-dimer levels were associated with lower disease control, lower objective response, and shorter progression-free survival in patients with advanced cSCC treated with cemiplimab. D-TECT is designed to prospectively validate this observation in a multicenter real-world cohort.

Eligible patients are adults with histologically confirmed locally advanced or metastatic cSCC for whom cemiplimab treatment is planned as part of routine clinical care. A D-dimer measurement is documented within 7 days before the first cemiplimab dose up to the day of first administration before infusion. Subsequent clinical data, including tumor response, progression, survival, treatment discontinuation, and thromboembolic events, are collected from routine medical records during follow-up.

The primary endpoint is disease control within the first 6 months after initiation of cemiplimab. The primary confirmatory analysis compares disease control between patients with high versus low pretreatment D-dimer values using the prespecified cutoff of 0.91 mg/L FEU derived from the prior single-center study. If the primary analysis is statistically significant, the same primary endpoint will be tested hierarchically using the local laboratory-defined upper limit of normal. Additional analyses include objective response rate, progression-free survival, overall survival, thromboembolic events, diagnostic performance measures of the predefined cutoffs, sensitivity analyses, and exploratory analyses addressing inter-site assay heterogeneity.

• Cutaneous Squamous Cell Carcinoma (CSCC)
• Advanced Cutaneous Squamous Cell Carcinoma
• Metastatic Cutaneous Squamous Cell Carcinoma

• Pretreatment D-dimer status

Ages Eligible for Study

Adult (18-64)Older Adult (65+)

Sexes Eligible for Study

All

Accepts Healthy Volunteers

No

Eligibility Criteria

Inclusion Criteria:

• Histologically confirmed locally advanced or metastatic cutaneous squamous cell carcinoma
• Planned initiation of systemic treatment with cemiplimab as part of routine clinical care
• Pretreatment D-dimer measurement performed within 7 days before initiation of cemiplimab treatment up to the day of first administration before infusion
• Age 18 years or older at the time of consent
• ECOG performance status 0 to 2
• Written informed consent for study participation and pseudonymized collection and analysis of clinical and laboratory data

Exclusion Criteria:

• Prior treatment with immune checkpoint inhibitors in curative or palliative intent for cutaneous squamous cell carcinoma
• Concurrent second malignancy requiring systemic treatment, such as chemotherapy, immunotherapy, or targeted therapy
• Clinically unstable comorbidity, including NYHA class III-IV heart failure or active systemic infection
• Acute symptomatic thrombosis or pulmonary embolism within 4 weeks before the pretreatment D-dimer measurement
• Incidental asymptomatic thromboembolic events detected during clinical diagnostic work-up or following an elevated D-dimer result are not exclusion criteria and will be documented
• Physician-estimated life expectancy of less than 3 months or severe non-tumor-related comorbidity likely to preclude assessment of the clinical course within the first 6 months
• Lack of capacity to consent or legal guardianship without valid legal representation

Observational Model

Cohort

Time Perspective

Prospective

Lead Sponsor

Universitätsklinikum Hamburg-EppendorfOTHER

selma.ugurel@klinikumbielefeld.de+49 (0)521 9438801

Michael.Sachse@klinikum-bremerhaven.de+49 (0)471 2993700

kai-martin.thoms@elbekliniken.de+49 (0)4161 7036250

onkstudienzentrale.DE@uk-erlangen.de+49 (0)9131 8533165

katharina.amschler@med.uni-goettingen.de+49 (0)551 3968082

g.geidel@uke.de+49 (0)40 741070743

vonWasielewski.Imke@mh-hannover.de+49 (0)5115320

Katharina.Kaehler@uksh.de+49 (0)431 50021131

DagmarAngela.vonbubnoff@uksh.de+49 (0)451 50041501

Henner.Stege@unimedizin-mainz.de+49 (0)6131 172919

jochen.utikal@umm.de+49 (0)621 3834461

dermatologie-minden@muehlenkreiskliniken.de+49 (0)571 7904501

Markus.Thieme@med.uni-rostock.de+49 (0) 381 494 9789

ulrike.leiter@med.uni-tuebingen.de+49 (0)7071 2984555

• Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

  NCT04975152

  RecruitingInterventionalPhase 1Updated Jun 25, 2026
• CemiplimAb Survivorship Epidemiology

  NCT03836105

  CompletedObservationalUpdated Oct 15, 2025
• Next-gen Flow Cytometry to Find Immune Profiles, Treatment Response, and Toxicity Markers in Skin Cancer Patients Treated With Cemiplimab.

  NCT07064330

  RecruitingObservationalUpdated Sep 10, 2025
• Evaluation of Efficacy and Safety of Cemiplimab as First Line Treatment for Advanced Basal Cell Carcinoma (BCC) Patients

  NCT06981325

  RecruitingInterventionalPhase 2Updated Mar 11, 2026
• Cemiplimab/Peg-Interferon-α in Advanced CSCC

  NCT05729139

  WithdrawnInterventionalPhase 1Updated Aug 9, 2023
• Neoadjuvant Merkel Cell Carcinoma Therapy (Tx) With the PD-1 Inhibitor Cemiplimab

  NCT07387198

  RecruitingInterventionalPhase 2Updated Jun 22, 2026